Abstract
An ever increasing number of molecular signatures are continuing to demonstrate the profound heterogeneity that characterizes acute myeloid leukemia (AML). The first significant advance in inducing remission in patients with AML included the combination of 7 days of cytosine arabinoside (ARAC) at 100 mg/m2 by continuous infusion along with three initial days of daunomycin at 45 mg/m2
| Original language | English (US) |
|---|---|
| Title of host publication | Evidence-Based Pediatric Oncology |
| Subtitle of host publication | Third Edition |
| Publisher | John Wiley and Sons |
| Pages | 117-125 |
| Number of pages | 9 |
| ISBN (Print) | 9780470659649 |
| DOIs | |
| State | Published - May 8 2013 |
| Externally published | Yes |
Keywords
- Acute myeloid leukemia (AML)
- Allogeneic transplantation
- Hematopoietic stem cell transplantation (HSCT)
- Postremission therapy
- Remission
ASJC Scopus subject areas
- General Medicine
Fingerprint
Dive into the research topics of 'Acute myeloid leukemia commentary'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS